Anthony Traboulsee

Tolebrutinib reduces new MRI lesions in highly active relapsing MS 2:28
Tolebrutinib reduces new MRI lesions in highly active relapsing MS
Anthony Traboulsee • 9 Apr 2021
Phase III trials of tolebrutinib in relapsing-remitting and progressive MS 2:20
Phase III trials of tolebrutinib in relapsing-remitting and progressive MS
Anthony Traboulsee • 9 Apr 2021
MOG antibody seropositivity in a multi-ethnic population 3:21
MOG antibody seropositivity in a multi-ethnic population
Anthony Traboulsee • 9 Apr 2021
Satralizumab in patients with NMOSD and concomitant autoimmune diseases 1:49
Satralizumab in patients with NMOSD and concomitant autoimmune diseases
Anthony Traboulsee • 9 Apr 2021
The content of VJNeurology is intended for healthcare professionals